Martinez, Anthony
Khan, Tipu
Dylla, Douglas E.
Marcinak, John
Collins, Michelle
Saget, Brad
Conway, Brian
Article History
Received: 26 July 2023
Accepted: 24 September 2023
First Online: 1 October 2023
Declarations
:
: Data used in this study are publicly available through the FAERS public dashboard so ethical approval was not required.
: Not applicable.
: AM has served as a speaker, a consultant and an advisory board member for Gilead, Intercept, Eisai, Salix, Bayer, BMS, Antios and AbbVie, and has received research funding from AbbVie, Gilead, Merck, Tobira, and Intercept. TK has served as a speaker, a consultant and an advisory board member for AbbVie, Indivior, and Alkermes. BC has received grants, honoraria, consultant fees and or/travel support from AbbVie, Gilead, Indivior, Merck, Sanofi Pasteur and ViiV Heathcare. DED, JM, MC, BS are full-time employees of AbbVie and may hold AbbVie stock and/or stock options.